PCS
VRTX icon

Personal CFO Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Personal CFO Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
2,120
+565
+36% +$250K 0.15% 122
2026
Q1 		$694K Buy
1,555
+211
+16% +$98.4K 0.1% 189
2025
Q4 		$609K Buy
1,344
+165
+14% +$71.1K 0.1% 200
2025
Q3 		$462K Buy
1,179
+42
+4% +$17.6K 0.08% 246
2025
Q2 		$506K Sell
1,137
-22
-2% -$10.1K 0.09% 221
2025
Q1 		$562K Buy
1,159
+92
+9% +$42.9K 0.11% 192
2024
Q4 		$430K Buy
1,067
+380
+55% +$176K 0.08% 230
2024
Q3 		$320K Buy
687
+24
+4% +$11.5K 0.04% 399
2024
Q2 		$311K Sell
663
-2
-0.3% -$868 0.05% 365
2024
Q1 		$278K Sell
665
-324
-33% -$137K 0.04% 420
2023
Q4 		$402K Sell
989
-74
-7% -$27.3K 0.07% 286
2023
Q3 		$370K Buy
1,063
+284
+36% +$99.3K 0.07% 270
2023
Q2 		$274K Sell
779
-69
-8% -$23.2K 0.06% 350
2023
Q1 		$267K Sell
848
-102
-11% -$30.6K 0.06% 348
2022
Q4 		$274K Buy
950
+2
+0.2% +$610 0.06% 329
2022
Q3 		$274K Buy
948
+3
+0.3% +$863 0.07% 271
2022
Q2 		$266K Sell
945
-801
-46% -$214K 0.06% 297
2022
Q1 		$456K Buy
1,746
+822
+89% +$195K 0.09% 214
2021
Q4 		$203K Buy
+924
New +$180K 0.04% 444
2021
Q2 		– Sell
-1,342
Closed -$288K – 470
2021
Q1 		$288K Buy
1,342
+453
+51% +$99.5K 0.06% 270
2020
Q4 		$210K Buy
889
+7
+0.8% +$1.61K 0.05% 342
2020
Q3 		$0 Buy
882
+149
+20% +$41.1K ﹤0.01% 326
2020
Q2 		$213K Buy
+733
New +$199K 0.06% 277

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Personal CFO Solutions's VRTX Position: Q2 2026 in Review

Personal CFO Solutions increased its Vertex Pharmaceuticals (VRTX) stake by 36% in Q2 2026, buying an estimated $250K and bringing the position to 2,120 shares worth $1.05M. The position accounts for 0.15% of the portfolio, ranked #122.

Personal CFO Solutions first reported a position in VRTX in Q2 2020 and has held it in 23 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Personal CFO Solutions held 2,120 shares of Vertex Pharmaceuticals worth $1.05M as of Q2 2026.
  • Personal CFO Solutions bought 565 Vertex Pharmaceuticals shares in Q2 2026, an estimated $250K.
  • Vertex Pharmaceuticals made up 0.15% of Personal CFO Solutions's portfolio in Q2 2026, its #122 holding.
  • Personal CFO Solutions first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Personal CFO Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.